biogen
present
positive
phase
systemic
lupus
erythematosus
data
american
college
rheumatology
meeting
phase
lilac
study
demonstrated
statistically
significant
reduction
joint
disease
activity
compared
placebo
systemic
lupus
erythematosus
patients
positive
results
build
previously
reported
cutaneous
lupus
erythematosus
data
underscore
biogen
commitment
lupus
community
systemic
lupus
erythematosus
chronic
debilitating
autoimmune
disease
affects
multiple
organ
systems
periods
illness
flares
alternating
periods
remission
cambridge
globe
newswire
today
biogen
nasdaq
biib
announced
positive
data
systemic
lupus
erythematosus
sle
portion
phase
lilac
study
part
demonstrating
associated
statistically
significant
reduction
total
active
joint
count
study
evaluated
efficacy
safety
humanized
monoclonal
antibody
mab
targeting
blood
dendritic
cell
antigen
expressed
exclusively
plasmacytoid
dendritic
cells
data
along
previously
reported
findings
cutaneous
lupus
erythematosus
cle
portion
lilac
study
presented
american
college
rheumatology
acr
convergence
held
virtually
november
people
living
systemic
lupus
erythematosus
suffer
chronic
debilitating
symptoms
impact
multiple
organ
systems
well
social
emotional
said
nathalie
franchimont
vice
president
head
multiple
sclerosis
immunology
development
unit
biogen
latest
data
highlight
potential
impact
disease
activity
together
earlier
cutaneous
lupus
erythematosus
findings
reflect
biogen
commitment
drive
therapeutic
innovation
lupus
patients
limited
treatment
phase
lilac
study
part
met
primary
endpoint
reducing
joint
disease
activity
individuals
sle
measured
total
active
joint
count
statistically
significant
difference
change
baseline
total
active
joint
count
observed
week
participants
received
mg
administered
subcutaneously
every
weeks
additional
dose
week
versus
placebo
total
active
joint
count
total
number
tender
swollen
joints
tender
swollen
joints
one
common
symptoms
impacting
quality
life
people
living
sle
study
also
met
secondary
endpoint
sle
responder
resulting
overall
reduction
disease
activity
participants
received
versus
placebo
percent
higher
response
rate
among
participants
received
percent
versus
placebo
percent
odds
composite
measure
comprising
criteria
different
internationally
validated
indices
systemic
disease
activity
additional
secondary
endpoint
part
study
individuals
sle
evaluated
effect
skin
disease
activity
using
cle
activity
disease
area
severity
score
subgroup
participants
baseline
score
percent
higher
response
rate
among
participants
received
percent
versus
placebo
percent
achieved
least
percent
improvement
response
however
statistical
significance
attained
odds
clinical
tool
measures
disease
activity
damage
cle
majority
adverse
events
lilac
study
mild
moderate
incidence
serious
adverse
events
percent
versus
percent
participants
received
versus
placebo
respectively
adverse
events
led
drug
discontinuation
observed
two
participants
received
three
participants
received
placebo
overall
efficacy
safety
tolerability
results
support
continued
clinical
development
sle
biogen
presentations
featured
acr
convergence
plenary
presentation
plenary
session
ii
abstract
efficacy
safety
results
phase
randomized
trial
dendritic
cell
antigen
antibody
sle
saturday
november
pm
eastern
time
et
oral
presentation
sle
treatment
session
abstract
humanized
monoclonal
antibody
binding
plasmacytoid
dendritic
cells
shows
efficacy
phase
study
participants
active
cutaneous
lupus
erythematosus
saturday
november
pm
pm
et
discovered
developed
exclusively
biogen
humanized
monoclonal
antibody
mab
targeting
blood
dendritic
cell
antigen
investigated
treatment
cutaneous
lupus
erythematosus
cle
systemic
lupus
erythematosus
sle
receptor
exclusively
expressed
subset
human
immune
cells
called
plasmacytoid
dendritic
cells
pdcs
shown
reduce
inflammatory
cytokine
production
pdcs
including
ifn
inflammatory
mediators
thought
play
major
role
pathogenesis
lupus
biogen
currently
planning
initiate
phase
program
phase
lilac
study
phase
lilac
study
randomized
study
enrolled
individuals
evaluate
safety
efficacy
versus
placebo
individuals
active
cutaneous
lupus
erythematosus
cle
including
chronic
subacute
subtypes
without
systemic
manifestations
part
b
individuals
systemic
lupus
erythematosus
sle
active
joint
skin
manifestations
part
sle
part
study
enrolled
patients
evaluated
mg
dose
versus
placebo
injected
subcutaneously
every
four
weeks
additional
dose
week
individuals
active
sle
primary
endpoint
change
baseline
total
active
joint
count
week
systemic
lupus
erythematosus
sle
cutaneous
lupus
erythematosus
cle
sle
chronic
autoimmune
disease
affects
multiple
organ
systems
periods
illness
flares
alternating
periods
remission
sle
present
several
ways
including
rash
arthritis
anemia
thrombocytopenia
serositis
nephritis
seizures
psychosis
sle
associated
greater
risk
death
causes
infection
cardiovascular
disease
cle
chronic
autoimmune
disease
body
immune
system
attacks
healthy
skin
often
causing
rashes
skin
lesions
painful
itchy
cle
associated
decrease
quality
life
increased
depression
forms
disease
patients
may
experience
scarring
skin
atrophy
alopecia
cle
may
occur
presence
frequently
absence
systemic
disease
biogen
biogen
mission
clear
pioneers
neuroscience
biogen
discovers
develops
delivers
worldwide
innovative
therapies
people
living
serious
neurological
neurodegenerative
diseases
well
related
therapeutic
adjacencies
one
world
first
global
biotechnology
companies
biogen
founded
charles
weissmann
heinz
schaller
kenneth
murray
nobel
prize
winners
walter
gilbert
phillip
sharp
today
biogen
leading
portfolio
medicines
treat
multiple
sclerosis
introduced
first
approved
treatment
spinal
muscular
atrophy
commercializes
biosimilars
advanced
biologics
focused
advancing
research
programs
multiple
sclerosis
neuroimmunology
alzheimer
disease
dementia
neuromuscular
disorders
movement
disorders
ophthalmology
immunology
neurocognitive
disorders
acute
neurology
pain
routinely
post
information
may
important
investors
website
follow
us
social
media
twitter
linkedin
facebook
youtube
biogen
safe
harbor
statement
news
release
contains
statements
including
statements
made
pursuant
safe
harbor
provisions
private
securities
litigation
reform
act
results
phase
lilac
study
potential
clinical
effects
potential
benefits
safety
efficacy
clinical
development
program
potential
commercial
business
pipeline
programs
including
strategy
plans
potential
commercial
business
pipeline
programs
including
risks
uncertainties
associated
drug
development
commercialization
statements
may
accompanied
words
aim
anticipate
believe
could
estimate
expect
forecast
goal
intend
may
plan
possible
potential
would
words
terms
similar
meaning
drug
development
commercialization
involve
high
degree
risk
small
number
research
development
programs
result
commercialization
product
results
early
stage
clinical
trials
may
indicative
full
results
results
later
stage
larger
scale
clinical
trials
ensure
regulatory
approval
place
undue
reliance
statements
scientific
data
presented
statements
involve
risks
uncertainties
could
cause
actual
results
differ
materially
reflected
statements
including
without
limitation
risks
relating
uncertainty
success
development
potential
commercialization
occurrence
adverse
safety
events
unexpected
concerns
may
arise
additional
data
analysis
failure
obtain
regulatory
approvals
risks
unexpected
hurdles
costs
delays
failure
protect
enforce
data
intellectual
property
proprietary
rights
uncertainties
relating
intellectual
property
claims
challenges
regulatory
authorities
may
require
additional
information
studies
may
fail
refuse
approve
may
delay
approval
drug
candidates
including
product
liability
claims
direct
indirect
impacts
ongoing
pandemic
business
results
operations
financial
condition
foregoing
sets
forth
many
factors
could
cause
actual
results
differ
expectations
statement
investors
consider
cautionary
statement
well
risk
factors
identified
recent
annual
quarterly
report
reports
filed
securities
exchange
commission
statements
based
current
beliefs
expectations
speak
date
news
release
undertake
obligation
publicly
update
statements
whether
result
new
information
future
developments
otherwise
